BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 31537801)

  • 1. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.
    Jung H; Kim HS; Kim JY; Sun JM; Ahn JS; Ahn MJ; Park K; Esteller M; Lee SH; Choi JK
    Nat Commun; 2019 Sep; 10(1):4278. PubMed ID: 31537801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy.
    Park C; Jeong K; Park JH; Jung S; Bae JM; Kim K; Ock CY; Kim M; Keam B; Kim TM; Jeon YK; Lee SH; Lee JS; Kim DW; Kang GH; Chung DH; Heo DS
    Cancer Immunol Immunother; 2021 Jun; 70(6):1605-1617. PubMed ID: 33230567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
    Mishra NK; Guda C
    Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites.
    Lee ST; Wiemels JL
    Nucleic Acids Res; 2016 Feb; 44(3):1105-17. PubMed ID: 26464434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
    Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
    PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of promoter CpG island hypermethylation in cancer: location, location, location!
    van Vlodrop IJ; Niessen HE; Derks S; Baldewijns MM; van Criekinge W; Herman JG; van Engeland M
    Clin Cancer Res; 2011 Jul; 17(13):4225-31. PubMed ID: 21558408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis Reveals Differential Susceptibility of Bidirectional Gene Promoters to DNA Methylation, Somatic Mutations, and Copy Number Alterations.
    Thompson JA; Christensen BC; Marsit CJ
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30081598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation aberrancies as a guide for surveillance and treatment of human cancers.
    Liang G; Weisenberger DJ
    Epigenetics; 2017 Jun; 12(6):416-432. PubMed ID: 28358281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma.
    Rhee YY; Lee TH; Song YS; Wen X; Kim H; Jheon S; Lee CT; Kim J; Cho NY; Chung JH; Kang GH
    Virchows Arch; 2015 Jun; 466(6):675-83. PubMed ID: 25772390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential methylation of CpG islands within the dermo1 gene promoter in several cancer cell lines.
    Mao Y; Toh HB; Ding Z; Sun L; Hong L; Chen CS; Wu X
    Oncol Rep; 2011 Jan; 25(1):107-11. PubMed ID: 21109964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia.
    Kushwaha G; Dozmorov M; Wren JD; Qiu J; Shi H; Xu D
    Hum Genomics; 2016 Jul; 10 Suppl 2(Suppl 2):18. PubMed ID: 27461342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors.
    Martin-Trujillo A; Vidal E; Monteagudo-Sánchez A; Sanchez-Delgado M; Moran S; Hernandez Mora JR; Heyn H; Guitart M; Esteller M; Monk D
    Nat Commun; 2017 Sep; 8(1):467. PubMed ID: 28883545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
    Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
    Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
    Schmitt K; Molfenter B; Laureano NK; Tawk B; Bieg M; Hostench XP; Weichenhan D; Ullrich ND; Shang V; Richter D; Stögbauer F; Schroeder L; de Bem Prunes B; Visioli F; Rados PV; Jou A; Plath M; Federspil PA; Thierauf J; Döscher J; Weissinger SE; Hoffmann TK; Wagner S; Wittekindt C; Ishaque N; Eils R; Klussmann JP; Holzinger D; Plass C; Abdollahi A; Freier K; Weichert W; Zaoui K; Hess J
    Int J Cancer; 2019 Dec; 145(12):3299-3310. PubMed ID: 31135957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered regulation of DNA ligase IV activity by aberrant promoter DNA methylation and gene amplification in colorectal cancer.
    Kuhmann C; Li C; Kloor M; Salou M; Weigel C; Schmidt CR; Ng LW; Tsui WW; Leung SY; Yuen ST; Becker N; Weichenhan D; Plass C; Schmezer P; Chan TL; Popanda O
    Hum Mol Genet; 2014 Apr; 23(8):2043-54. PubMed ID: 24282031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA hypomethylation in cancer cells.
    Ehrlich M
    Epigenomics; 2009 Dec; 1(2):239-59. PubMed ID: 20495664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.